Compare RTO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTO | NBIX |
|---|---|---|
| Founded | 1925 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 15.5B |
| IPO Year | 2002 | 1996 |
| Metric | RTO | NBIX |
|---|---|---|
| Price | $22.78 | $155.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 22 |
| Target Price | $35.00 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 03-09-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $17.05 | $24.73 |
| Revenue Next Year | $4.35 | $13.14 |
| P/E Ratio | $222.16 | ★ $47.01 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $23.07 | $122.14 |
| 52 Week High | $34.67 | $186.12 |
| Indicator | RTO | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 41.96 |
| Support Level | N/A | $152.67 |
| Resistance Level | $24.22 | $161.29 |
| Average True Range (ATR) | 0.38 | 3.87 |
| MACD | 0.12 | 0.61 |
| Stochastic Oscillator | 1.17 | 30.39 |
Rentokil Initial is the largest global provider of route-based pest control and commercial hygiene services, operating in over 90 countries, with its largest operations in the United States following the acquisition of Terminix. The group also offers a range of specialist route-based services, including office and commercial space plant care, property care, and workwear rentals. The group serves a diverse client base of global food producers, hotel chains, industrial goods companies, restaurants, and individual residential customers.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.